Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naive patients

Research output: Contribution to journalArticle

157 Citations (Scopus)

Abstract

The coadministration of ribavirin with recombinant interferon alfa-2b (rIFN-α2b) compared with rIFN-α2b alone markedly enhanced sustained virologic response rates in relapsed and treatment-naive chronic hepatitis C patients. The potential for ribavirin to likewise exacerbate the adverse events associated with the alpha interferons is reviewed. The overall safety and tolerability of combination rIFN-α2b/ribavirin therapy was evaluated in 2,089 patients treated in phase III clinical studies conducted in the United States and internationally. Serious adverse events were also evaluated on an interim basis in > 25,000 patients - a majority of whom were treated with combination therapy (open label) - treated worldwide in investigator- initiated studies. Patients in the phase III studies received 3 million International Units rIFN-α2b three times per week by subcutaneous injection plus either ribavirin or placebo orally in divided daily doses of 1,000 or 1,200 mg for patients weighing ≤ 75 or > 75 kg, respectively. Adverse event frequency and severity and dose modifications were recorded throughout the 24-week (relapse) or 48-week (naive) treatment period and 24-week follow-up period. Clinically significant adverse events included anemia and depression. There was no evidence that the adverse effects of alpha interferon (eg, fatigue, depression, neutropenia) were exacerbated by ribavirin. Severe adverse events were limited due to strict adherence to dose-modification criteria; approximately 6% to 9% of patients discontinued combination therapy because of an adverse event. Clinically serious adverse events, dose reductions and discontinuations, and potential mechanisms of toxicity associated with rIFN-α2b and ribavirin are examined.

Original languageEnglish (US)
Pages (from-to)67-76
Number of pages10
JournalSeminars in Liver Disease
Volume19
Issue number1 SUPPL. 1
StatePublished - 1999

Fingerprint

interferon alfa-2b
Ribavirin
Chronic Hepatitis C
Safety
Interferon-alpha
Therapeutics
Subcutaneous Injections
Neutropenia
Fatigue
Anemia
Placebos
Research Personnel

Keywords

  • Interferon
  • Ribavirin
  • Safety
  • Tolerability

ASJC Scopus subject areas

  • Hepatology

Cite this

@article{a218c47988aa435a802a6f5c06f022d9,
title = "Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naive patients",
abstract = "The coadministration of ribavirin with recombinant interferon alfa-2b (rIFN-α2b) compared with rIFN-α2b alone markedly enhanced sustained virologic response rates in relapsed and treatment-naive chronic hepatitis C patients. The potential for ribavirin to likewise exacerbate the adverse events associated with the alpha interferons is reviewed. The overall safety and tolerability of combination rIFN-α2b/ribavirin therapy was evaluated in 2,089 patients treated in phase III clinical studies conducted in the United States and internationally. Serious adverse events were also evaluated on an interim basis in > 25,000 patients - a majority of whom were treated with combination therapy (open label) - treated worldwide in investigator- initiated studies. Patients in the phase III studies received 3 million International Units rIFN-α2b three times per week by subcutaneous injection plus either ribavirin or placebo orally in divided daily doses of 1,000 or 1,200 mg for patients weighing ≤ 75 or > 75 kg, respectively. Adverse event frequency and severity and dose modifications were recorded throughout the 24-week (relapse) or 48-week (naive) treatment period and 24-week follow-up period. Clinically significant adverse events included anemia and depression. There was no evidence that the adverse effects of alpha interferon (eg, fatigue, depression, neutropenia) were exacerbated by ribavirin. Severe adverse events were limited due to strict adherence to dose-modification criteria; approximately 6{\%} to 9{\%} of patients discontinued combination therapy because of an adverse event. Clinically serious adverse events, dose reductions and discontinuations, and potential mechanisms of toxicity associated with rIFN-α2b and ribavirin are examined.",
keywords = "Interferon, Ribavirin, Safety, Tolerability",
author = "Maddrey, {Willis C.}",
year = "1999",
language = "English (US)",
volume = "19",
pages = "67--76",
journal = "Seminars in Liver Disease",
issn = "0272-8087",
publisher = "Thieme Medical Publishers",
number = "1 SUPPL. 1",

}

TY - JOUR

T1 - Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naive patients

AU - Maddrey, Willis C.

PY - 1999

Y1 - 1999

N2 - The coadministration of ribavirin with recombinant interferon alfa-2b (rIFN-α2b) compared with rIFN-α2b alone markedly enhanced sustained virologic response rates in relapsed and treatment-naive chronic hepatitis C patients. The potential for ribavirin to likewise exacerbate the adverse events associated with the alpha interferons is reviewed. The overall safety and tolerability of combination rIFN-α2b/ribavirin therapy was evaluated in 2,089 patients treated in phase III clinical studies conducted in the United States and internationally. Serious adverse events were also evaluated on an interim basis in > 25,000 patients - a majority of whom were treated with combination therapy (open label) - treated worldwide in investigator- initiated studies. Patients in the phase III studies received 3 million International Units rIFN-α2b three times per week by subcutaneous injection plus either ribavirin or placebo orally in divided daily doses of 1,000 or 1,200 mg for patients weighing ≤ 75 or > 75 kg, respectively. Adverse event frequency and severity and dose modifications were recorded throughout the 24-week (relapse) or 48-week (naive) treatment period and 24-week follow-up period. Clinically significant adverse events included anemia and depression. There was no evidence that the adverse effects of alpha interferon (eg, fatigue, depression, neutropenia) were exacerbated by ribavirin. Severe adverse events were limited due to strict adherence to dose-modification criteria; approximately 6% to 9% of patients discontinued combination therapy because of an adverse event. Clinically serious adverse events, dose reductions and discontinuations, and potential mechanisms of toxicity associated with rIFN-α2b and ribavirin are examined.

AB - The coadministration of ribavirin with recombinant interferon alfa-2b (rIFN-α2b) compared with rIFN-α2b alone markedly enhanced sustained virologic response rates in relapsed and treatment-naive chronic hepatitis C patients. The potential for ribavirin to likewise exacerbate the adverse events associated with the alpha interferons is reviewed. The overall safety and tolerability of combination rIFN-α2b/ribavirin therapy was evaluated in 2,089 patients treated in phase III clinical studies conducted in the United States and internationally. Serious adverse events were also evaluated on an interim basis in > 25,000 patients - a majority of whom were treated with combination therapy (open label) - treated worldwide in investigator- initiated studies. Patients in the phase III studies received 3 million International Units rIFN-α2b three times per week by subcutaneous injection plus either ribavirin or placebo orally in divided daily doses of 1,000 or 1,200 mg for patients weighing ≤ 75 or > 75 kg, respectively. Adverse event frequency and severity and dose modifications were recorded throughout the 24-week (relapse) or 48-week (naive) treatment period and 24-week follow-up period. Clinically significant adverse events included anemia and depression. There was no evidence that the adverse effects of alpha interferon (eg, fatigue, depression, neutropenia) were exacerbated by ribavirin. Severe adverse events were limited due to strict adherence to dose-modification criteria; approximately 6% to 9% of patients discontinued combination therapy because of an adverse event. Clinically serious adverse events, dose reductions and discontinuations, and potential mechanisms of toxicity associated with rIFN-α2b and ribavirin are examined.

KW - Interferon

KW - Ribavirin

KW - Safety

KW - Tolerability

UR - http://www.scopus.com/inward/record.url?scp=0032895782&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032895782&partnerID=8YFLogxK

M3 - Article

VL - 19

SP - 67

EP - 76

JO - Seminars in Liver Disease

JF - Seminars in Liver Disease

SN - 0272-8087

IS - 1 SUPPL. 1

ER -